CareDx, Inc. (CDNA) company profile

CareDx, Inc. is a precision medicine company specializing in solutions for transplant patients and organ health management. Operating as a single reportable segment, the organization provides non-invasive molecular testing, laboratory products, digital health applications, and specialized pharmacy services across the pre- and post-transplant continuum. Its commercial testing portfolio includes gene expression profiling and donor-derived cell-free DNA tests for kidney, heart, and lung transplant surveillance. Additionally, the company offers human leukocyte antigen typing products, diagnostic next-generation sequencing kits, and clinical workflow software. CareDx serves clinicians, transplant centers, dialysis centers, healthcare providers, and biopharmaceutical partners.

The company operates primarily across the United States and Europe, with its main assets and operations situated in the United States and Sweden. Its digital health software is utilized in more than 170 transplant facilities throughout the United States. CareDx maintains primary operations in Brisbane, California; Omaha, Nebraska; and Stockholm, Sweden, with its corporate headquarters located in Brisbane, California.

Summary of the business section of CareDx's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“On December 31, 2025, we had 765 employees, of which 761 were full-time employees.”